Table 1.
Clinical cohort
| High fatigue | Low fatigue | |
|---|---|---|
| Age at Baseline, median (IQR) | 65 (56–71) | 66 (58–71) |
| Sex | ||
| Male, n (%) | 14 (64) | 14 (64) |
| Female, n (%) | 8 [36] | 8 [36] |
| Presentation | ||
| Right hemisphere, n (%) | 13 (59%) | 10 (45%) |
| Left hemisphere, n (%) | 9 (41%) | 10 (45%) |
| Bilateral, n (%) | 0 (0%) | 2 (9%) |
| NIHSS, median (IQR) | 5 [2–11] | 4 [2–13] |
| Infarct volume (mL), median (IQR) | 5.5 (0.46–39.08) | 7.2 (1.98–42.33) |
| Days from Stroke to Baseline, median (IQR) | 316 (235–1062) | 256 (206–1236) |
| IV thrombolysis, n (%) | 4 (20%) | 8 (38%) |
| IA thrombectomy, n (%) | 4 (20%) | 6 (29%) |
| Risk Factors | ||
| Hypertension, n (%) | 15 (75%) | 9 (43%) |
| Previous stroke, n (%) | 4 (24%) | 2 (12%) |
| Atrial fibrillation, n (%) | 3 (17%) | 5 (24%) |
| Hyperlipidaemia, n (%) | 9 (53%) | 6 (29%) |
| Other cardiovascular diseases, n (%) | 2 (12%) | 3 (17%) |
| Heart valve repair/replacement, n (%) | 1 (5%) | 2 (9%) |
| Angina, n (%) | 0 (0%) | 0 (%) |
| Congestive heart failure, n (%) | 1 (5%) | 1 (5%) |
| Pacemaker and/or defibrillator, n (%) | 0 (0%) | 2 (9%) |
| Coronary angioplasty, n (%) | 3 (15%) | 4 (18%) |
| Medications | ||
| Antiplatelets, n (%) | 6 (27%) | 5 (23%) |
| Anticoagulants, n (%) | 1 (5%) | 2 (9%) |
| Statin, n (%) | 18 (82%) | 16 (73%) |
| Beta-blocker, n (%) | 6 (27%) | 6 (27%) |
| ACE-inhibitor, n (%) | 4 (18%) | 4 (18%) |
| Angiotensin II receptor blocker, n (%) | 6 (27%) | 4 (18%) |
Median and interquartile range (IQR), analysed by Mann-Whitney test for nonparametric data and Fisher’s exact test for categorical data. NIHSS: National Institutes of Health Stroke Scale; IV: intravenous; IA: intra-arterial; ACE: Angiotensin Converting Enzyme